Clinical trial · Observational
The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy
The Impact of Hepatic Steatosis on Survival After Pancreaticoduodenectomy for Resectable Pancreatic Cancer. A Multifactorial Analysis of Metabolic Dysfunction
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We will use simple summaries, educational handouts, and discussions with doctors and nurses to explain this study. The study looks at patients with early-stage pancreatic cancer who undergo pancreaticoduodenectomy (Whipple surgery). We found that some patients develop fatty liver (non-alcoholic fatty liver disease, NAFLD) within six months after surgery, which can affect nutrition, blood sugar control, and long-term survival. To help patients and families understand, we will: 1. Provide clear written information sheets about the purpose of the study and its findings. 2. Use diagrams or plain-language explanations of terms like "pancreatic exocrine function" and "fatty liver." 3. Share results with healthcare providers so they can guide patients in nutrition, enzyme replacement, diabetes monitoring, and follow-up care. 4. Offer contact information for the research team to answer questions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pancreaticoduodenectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence of postoperative nonalcoholic fatty liver disease (NAFLD)
- timeFrame
- 6 months after pancreaticoduodenectomy
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Adults with stage I-II pancreatic ductal adenocarcinoma. * Underwent curative-intent pancreaticoduodenectomy (conventional or pylorus-preserving). * Surgery between January 2015 and May 2023. * Complete clinical and imaging data available. * Survived at least 6 months postoperatively. Exclusion Criteria: * Preoperative hepatic steatosis * Incomplete clinical or imaging data * Death within 6 months after surgery
References
Publications (0)
Data not yet available